Compositions comprising nanostructures for cell, tissue and artificial organ growth, and methods for making and using same

Patent metadata

Field	Value
Publication number	US-9273277-B2
Application number	US-201313858042-A
Country	US
Kind code	B2
Filing date	Apr 6, 2013
Priority date	Apr 28, 2005
Publication date	Mar 1, 2016
Grant date	Mar 1, 2016

Abstract

The invention provides articles of manufacture comprising biocompatible nanostructures comprising nanotubes and nanopores for, e.g., organ, tissue and/or cell growth, e.g., for bone, kidney or liver growth, and uses thereof, e.g., for in vitro testing, in vivo implants, including their use in making and using artificial organs, and related therapeutics. The invention provides lock-in nanostructures comprising a plurality of nanopores or nanotubes, wherein the nanopore or nanotube entrance has a smaller diameter or size than the rest (the interior) of the nanopore or nanotube. The invention also provides dual structured biomaterial comprising micro- or macro-pores and nanopores. The invention provides biomaterials having a surface comprising a plurality of enlarged diameter nanopores and/or nanotubes.

First claim

What is claimed is:

1. A lock-in nanostructure comprising a plurality of nanotubes, wherein:
(a) at least a nanotube of the plurality of nanotubes has a locked-in nanotube entrance that is smaller in size than an interior of the nanotube to exhibit a re-entrant configuration;
(b) the plurality of nanotubes have an outer diameter of between about 10 to 1000 nm;
(c) a height of at least a nanotube of the plurality of nanotubes has a height of at least about 40 nm;
(v) a vertical alignment angle of at least a nanotube of the plurality of nanotubes is within from about 0 to 45 degrees off a vertical direction, or about 5, 10, 15, 20, 25, 30 or 35 degrees variation off a perpendicular axis; and
(vi) a lateral spacing between adjacent nanotubes of the plurality of nanotubes is from about 2 to 100 nm.

2. The lock-in nanostructure of claim 1 , wherein the locked-in nanotube entrance has an average entrance diameter that is at least 10% to 50% smaller than the interior of the nanotube.

3. The lock-in nanostructure of claim 1 , wherein the plurality of nanotubes comprise a Ti or a TiO 2 .

4. A dual structured biomaterial comprising:
(a) a plurality of micro-pores, wherein the plurality of micro-pores has an average or equivalent diameter of between about 0.5-1,000 μm (microns); and
(b) a surface area at least 10% covered with a plurality of nanotubes, wherein
(i) the plurality of nanotubes have an outer diameter of between about 10 to 1000 nm;
(ii) the height of at least a nanotube of the plurality of nanotubes has a height of at least about 40 nm;
(iii) a vertical alignment angle of at least a nanotube of the plurality of nanotubes is within from about 0 to 45 degrees off a vertical direction, or about 5, 10, 15, 20, 25, 30 or 35 degrees variation off a perpendicular axis; and
(iv) a lateral spacing between adjacent nanotubes of the plurality of nanotubes is from about 2 to 100 nm.

5. The dual structured biomaterial of claim 4 , wherein the dual structured biomaterial comprises, or is contained within, an implant any of an artificial organ and a joint.

6. The lock-in nanostructure of claim 1 , further comprising a plurality of cells.

7. An implant comprising the lock-in nanostructure of claim 1 .

8. A bioreactor comprising the lock-in nanostructure of claim 1 .

9. An artificial organ comprising the lock-in nanostructure of claim 1 .

10. A disease detection device comprising the lock-in nanostructure of claim 1 , wherein optionally the disease detected is influenza (flu), SARS or anthrax.

11. The lock-in nanostructure of 1 , wherein the nanotube entrance has an average entrance diameter that is at least about 15%, 20%, 25%, 30%, 35%, 40% or 45%, smaller than the interior of the nanotube.

12. The lock-in nanostructure of 1 , wherein the lock-in nanostructure comprises, or is part of, any of an implant, an artificial organ and a joint.

13. The dual structured biomaterial of claim 4 , wherein:
(a) each of the plurality of nanotubes has an average pore diameter of between about 30-600 nm;
(b) the relative ratio of the plurality of micro-pores and the plurality of nanotubes is such that the plurality of micro-pores occupy at least about a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% area fraction of the dual structured biomaterial; or,
(c) the relative ratio of the plurality of micro-pores is such that the plurality of micro-pores occupy at least about a 20% but less than about a 50% area fraction of the dual structured biomaterial.

14. An implant comprising the dual structured biomaterial of claim 4 .

15. A bioreactor comprising the dual structured biomaterial of claim 4 .

16. An artificial organ comprising the dual structured biomaterial of claim 4 .

17. A disease detection device comprising the dual structured biomaterial of claim 4 , wherein optionally the disease detected is influenza (flu), SARS or anthrax.

18. The dual structured biomaterial of claim 4 , wherein each micro-pore of the plurality of micro-pores has an entrance that is smaller in size than an interior of the micro-pore.

19. The lock-in nanostructure of 6 , wherein the plurality of cells comprise any of liver cells, liver parenchymal cells, endothelial cells, adipocytes, fibroblastic cells, Kupffer cells, kidney cells, blood vessel cells, skin cells, periodontal cells, odontoblasts, dentinoblasts, cementoblasts, enameloblasts, odontogenic ectomesenchymal tissue, osteoblasts, osteoclasts, fibroblasts, a cell or a tissue involved in odontogenesis or bone formation, stem cells and a combination thereof.

20. The dual structured biomaterial of claim 4 , further comprising a plurality of cells.

21. The lock-in nanostructure of claim 1 , wherein the height of a nanotube of the plurality of nanotubes between about 40 to 2000 nm.

22. The dual structured biomaterial of claim 4 , wherein the height of a nanotube of the plurality of nanotubes is between about 40 to 2000 nm.

23. A biocompatible vertically aligned nanotube array structure on a biocompatible substrate comprising a plurality of nanotubes in a laterally separated nanotube arrangement wherein:
(a) a nanotube of the plurality of nanotubes has an outer diameter of between about 10 to 1000 nm;
(b) the height of a nanotube of the plurality of nanotubes has a height of at least about 40 nm;
(c) a vertical alignment angle of at least a nanotube of the plurality of nanotubes is within from about 0 to 45 degrees off a vertical direction, or about 5, 10, 15, 20, 25, 30 or 35 degrees variation off a perpendicular axis; and
(d) a lateral spacing between adjacent nanotubes of the plurality of nanotubes is from about 2 to 100 nm.

24. The biocompatible vertically aligned nanotube array of claim 23 , wherein the height of a nanotube of the plurality of nanotubes is between about 40 to 2000 nm.

25. The biocompatible vertically aligned nanotube array structure of claim 23 , wherein:
(a) the plurality of nanotubes comprise a plurality of biocompatible titanium oxide nanotubes;
(b) a nanotube of the plurality of nanotubes has an outer diameter of at least about 20, 30, 40, 50, 60, 70, 80, 90 or 100 nm;
(c) a nanotube of the plurality of nanotubes has an outer diameter of between about 10 to 100 nm outer diameter;
(d) a nanotube of the plurality of nanotubes has an inner diameter of between about 20, 30, 40, 50, 60, 70, 80, 90 or 100 nm;
(e) a nanotube of the plurality of nanotubes has an inner diameter of between about 10 to about 90 nm;
(f) a nanotube of the plurality of nanotubes has a wall thickness of at least about 10, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nm;
(g) t a nanotube of the plurality of nanotubes has a wall thickness of between about 10 to 100 nm;
(h) a nanotube of the plurality of nanotubes has a height of about 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225 or 250 nm;
(j) a nanotube of the plurality of nanotubes has a height of between about 20 to 300 nm;
(j) the biocompatible substrate comprises a titanium sheet;
(k) the biocompatible substrate is at least about 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225 or more nm thick;
(l) at least about 10% of the biocompatible substrate comprises nanotubes; or
(m) the biocompatible vertically aligned nanotube array structure comprises any combination of (a) to (l).

Assignees

• Univ California

Inventors

• Jin Sungho
• Oh Seunghan

Classifications

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61L27/306

  Other specific inorganic materials not covered by A61L27/303 - A61L27/32 · CPC title

• C12M23/34 Primary

  Internal compartments or partitions · CPC title

• A61L27/06

  Titanium or titanium alloys · CPC title